Thursday, April 29, 2010
Conventional wisdom holds that the only way to generate new
islet cells in people with type 1 diabetes is through cell therapy. A trio of
recent deals, however, suggests that some companies and not-for-profit
organizations are betting on a different approach. All three collaborations
involve the use of small molecules or peptides to accomplish the task of making
Minding the INGAP
S. SciBX 3(17); doi:10.1038/scibx.2010.515
Published online April 29, 2010
T. et al. J. Clin. Invest. 117, 2553-2561 (2007)
R. et al. J. Clin. Invest. 99, 2100-2109 (1997)
COMPANIES AND INSTITUTIONS MENTIONED
CureDM Inc., Wilmington, Del.
Eastern Virginia Medical School, Norfolk, Va.
Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind.
Exsulin Corp., Minneapolis, Minn.
Fate Therapeutics Inc., San Diego, Calif.
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London,
Juvenile Diabetes Research Foundation International, New York, N.Y.
Medical Organization, Jerusalem, Israel
Hebrew University of Jerusalem, Jerusalem, Israel
MacroGenics Inc., Rockville, Md.
McGill University, Montreal, Quebec, Canada
Pfizer Inc. (NYSE:PFE), New York, N.Y.
Procter & Gamble Co. (NYSE:PG), Cincinnati, Ohio
sanofi-aventis Group (Euronext:SAN; NYSE:SNY), Paris,
Tolerx Inc., Cambridge, Mass.
Verio Therapeutics Inc., Ottawa, Ontario, Canada